After combing through 4,000 existing medications, an artificial intelligence tool helped uncover one that saved the life of a patient with idiopathic multicentric Castleman's disease (iMCD).

Mirikizumab showed superior maintenance efficacy over most treatments for ulcerative colitis (UC), according to a network ...

Set to enter hospice care, a patient with idiopathic multicentric Castleman's disease is now in remission after treatment with a medication identified by an AI-guided analysis.

Mozart Therapeutics, the leading developer of CD8 Treg network modulators in autoimmune disease, announces the presentation of new preclinical data for MTX-201, a bispecific antibody that antagonizes ...

The patient has iMCD, which has a poor survival rate and few treatment options but an AI tool searched through 4,000 ...

Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue(i) grew by 20% compared to Q4 2023. Pipeline ...

Lilly's fourth-quarter earnings, released before the market opened Thursday, surpassed analysts' expectations by millions.

Researchers used an AI-driven approach to identify adalimumab as a potential life-saving treatment for idiopathic ...

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to ...

Eli Lilly is setting the stage for a strong 2025, with its fourth-quarter results and forward guidance reflecting solid momentum. The company's adjusted earnings per share are exp ...